Sanofi is back with its second pact of the day, this time announcing a licensing deal for a South Korean biotech’s antibody ...

An investor whose portfolio contains some value- or income-focused investments and some growth-oriented investments, who ...

Novartis has tapped up an AI-enabled British biotech for a $1.7 billion biobucks deal to discover new targets for ...

Data demonstrates the significant and sustained tumor regression achieved by the CAPTN-3 platform across two distinct tri-specific antibodies, IM1240 and IM1305, targeting different tumor antigens ...